Tofacitinib
JAK inhibitor (JAK1/JAK3)
- Response rate
- Promising (case series only)
- Onset
- Weeks
- Route
- Oral 5-10mg twice daily
- Line
- Investigational
- IgM effect
- Suppresses inflammatory biomarkers
Evidence summary
JAK inhibitor showing promise in colchicine-resistant FMF. Three independent case series (6 patients total) reported marked suppression of inflammatory biomarkers and sustained clinical remission. Oral administration is an advantage. Larger controlled trials needed.